Could a daily pill tame advanced breast cancer? new trial tests oral paclitaxel
NCT ID NCT07602907
First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to see if it can delay cancer growth. About 44 adults who have already tried other treatments will participate, with regular checkups to monitor safety and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Paclitaxel oral solution and toripalimab (an immunotherapy drug)
- What this could lead to
- If successful, this could offer a more convenient oral chemotherapy option and a new combination therapy to slow cancer growth in advanced HER2-negative breast cancer.
- What could go wrong
- This is an early Phase 2 trial with only 44 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes compared to existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- Heating up tumors: could thermal therapy boost immune attack on breast cancer?